| Clinical practice recommendation | Issues to be addressed in future studies |
---|---|---|
Diagnosis | •NBS via SA to avoid sequelae including HCC |  |
Treatment & Monitoring | •NTBC & diet | •Calculation Tyr & Phe vs protein restriction |
•NTBC-level 20-40 μM | •NTBC-target level | |
•Tyr-level < 400 μM | •Tyr-target level | |
•SA below detection limit | •SA target level | |
•Contrast enhanced ultrasound & AFP | •Correlation NTB-levels & side effects | |
•Liver & Kidney function | •NTBC- pharmacokinetics in children | |
Liver transplantation | •HCC | •NTBC & diet if SA-elevation post transplant |
•Therapy resistance | ||
Outcome | •Psychomotor/neurocognitive assessment | •Pathophysiology of neurological damage and risk factors |
•Definition of adequate test battery | ||
Reimbursement | •Diagnosis & Treatment & Monitoring |  |